ChemoCentryx (CCXI) versus Stellar Biotechnologies (SBOT) Financial Contrast


ChemoCentryx (NASDAQ: CCXI) and Stellar Biotechnologies (NASDAQ:SBOT) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their risk, dividends, profitability, valuation, institutional ownership, earnings and analyst recommendations.

Analyst Ratings

This is a summary of recent ratings and recommmendations for ChemoCentryx and Stellar Biotechnologies, as provided by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
ChemoCentryx 0 1 3 1 3.00
Stellar Biotechnologies 0 0 0 0 N/A

ChemoCentryx presently has a consensus price target of $17.75, indicating a potential upside of 56.11%. Given ChemoCentryx’s higher probable upside, equities analysts plainly believe ChemoCentryx is more favorable than Stellar Biotechnologies.

Valuation and Earnings

This table compares ChemoCentryx and Stellar Biotechnologies’ top-line revenue, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
ChemoCentryx $82.50 million 6.77 $17.69 million $0.36 31.58
Stellar Biotechnologies $230,000.00 22.17 -$5.03 million ($3.43) -0.45

ChemoCentryx has higher revenue and earnings than Stellar Biotechnologies. Stellar Biotechnologies is trading at a lower price-to-earnings ratio than ChemoCentryx, indicating that it is currently the more affordable of the two stocks.

Institutional and Insider Ownership

50.3% of ChemoCentryx shares are owned by institutional investors. Comparatively, 6.9% of Stellar Biotechnologies shares are owned by institutional investors. 14.5% of ChemoCentryx shares are owned by insiders. Comparatively, 7.8% of Stellar Biotechnologies shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Volatility & Risk

ChemoCentryx has a beta of 1.69, suggesting that its share price is 69% more volatile than the S&P 500. Comparatively, Stellar Biotechnologies has a beta of 0.22, suggesting that its share price is 78% less volatile than the S&P 500.

Profitability

This table compares ChemoCentryx and Stellar Biotechnologies’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
ChemoCentryx N/A 31.56% 9.03%
Stellar Biotechnologies -4,766.06% -77.77% -72.53%

Summary

ChemoCentryx beats Stellar Biotechnologies on 13 of the 14 factors compared between the two stocks.

ChemoCentryx Company Profile

ChemoCentryx, Inc., a clinical-stage biopharmaceutical company, develops new medications for inflammatory and autoimmune diseases, and cancer in the United States. The company targets the chemokine and chemoattractant systems to discover, develop, and commercialize orally-administered therapies. Its lead drug candidate is Avacopan, an orally-administered complement inhibitor of the complement C5a receptor (C5aR), is in Phase III development for the treatment of anti-neutrophil cytoplasmic auto-antibody-associated vasculitis (AAV). The company is also developing Avacopan for the treatment of patients with C3 glomerulopathy (C3G), hidradenitis suppurativa (HS), and in atypical hemolytic uremic syndrome (aHUS). In addition, the company is developing CCX140, an inhibitor of the chemokine receptor known as CCR2, which has completed a Phase II clinical trial in diabetic nephropathy (DN) and is being developed for patients with focal segmental glomerulosclerosis (FSGS). Further, it has early stage drug candidates that target chemoattractant receptors in other inflammatory and autoimmune diseases, and in cancer. The company was founded in 1997 and is headquartered in Mountain View, California.

Stellar Biotechnologies Company Profile

Stellar Biotechnologies, Inc., a biotechnology company, engages in the aquaculture, research and development, manufacture, and commercialization of keyhole limpet hemocyanin (KLH) protein in Europe, North America, and Asia. The company offers KLH, an immune-stimulating protein used in the production of various immunotherapies; and as a carrier molecule or finished injectable product in the immunodiagnostic market. It provides its KLH protein under the Stellar KLH brand. The company’s products include Stellar KLH protein in various grades, formulations, custom configurations, and fill finishes for drug development and research applications, as well as KLH-based in vitro diagnostic kits for research and preclinical use. Its customers and partners comprise biotechnology and pharmaceutical companies, academic institutions, clinical research organizations, and research centers. Stellar Biotechnologies, Inc. is based in Port Hueneme, California.

Receive News & Ratings for ChemoCentryx Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for ChemoCentryx and related companies with MarketBeat.com’s FREE daily email newsletter.





Source link

0 replies

Leave a Reply

Want to join the discussion?
Feel free to contribute!

Leave a Reply

Your email address will not be published. Required fields are marked *